# Role of Perhexiline in Hypertrophic Cardiomyopathy

> **NCT04426578** · PHASE2 · UNKNOWN · sponsor: **Flinders University** · enrollment: 60 (estimated)

## Conditions studied

- Hypertrophic Cardiomyopathy

## Interventions

- **DRUG:** Perhexiline
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04426578
- **Lead sponsor:** Flinders University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04426578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04426578, "Role of Perhexiline in Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04426578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*